TY - JOUR
T1 - Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer
AU - Carillo, Viviana
AU - Cozzarini, Cesare
AU - Rancati, Tiziana
AU - Avuzzi, Barbara
AU - Botti, Andrea
AU - Borca, Valeria Casanova
AU - Cattari, Gabriella
AU - Civardi, Francesco
AU - Esposti, Claudio Degli
AU - Franco, Pierfrancesco
AU - Girelli, Giuseppe
AU - Maggio, Angelo
AU - Muraglia, Alessandro
AU - Palombarini, Marcella
AU - Pierelli, Alessio
AU - Pignoli, Emanuele
AU - Vavassori, Vittorio
AU - Zeverino, Michele
AU - Valdagni, Riccardo
AU - Fiorino, Claudio
N1 - Funding Information:
The study was supported by the Associazione Italiana Ricerca sul Cancro ( AIRC-IG13090 ). We also acknowledge Cinzia Bianconi for data management and Frank Bagg for the linguistic revision.
PY - 2014/4
Y1 - 2014/4
N2 - Background and purpose DUE01 is an observational study aimed at developing predictive models of genito-urinary toxicity of patients treated for prostate cancer with conventional (1.8-2 Gy/fr, CONV) or moderate hypo-fractionation (2.35-2.7 Gy/fr, HYPO). The current analysis focused on the relationship between bladder DVH/DSH and the risk of International Prostate Symptoms Score (IPSS) ≥ 15/20 at the end of radiotherapy. Materials and methods Planning and relevant clinical parameters were prospectively collected, including DVH/DSH, LQ-corrected (DVHc/DSHc) and weekly (DVHw/DSHw) histograms. Best parameters were selected by the differences between patients with/without IPSS ≥ 15/20 at the end of radiotherapy. Logistic uni- and backward multi-variable (MVA) analyses were performed. Results Data of 247 patients were available (CONV: 116, HYPO: 131). Absolute DVHw/DSHw and DVHc/DSHc predicted the risk of IPSS ≥ 15 at the end of radiotherapy (n = 77/247); an MVA model including baseline IPSS, anti-hypertensive, T stage, the absolute surface receiving ≥8.5 Gy/week and ≥12.5 Gy/week was developed (AUC = 0.78, 95% CI: 0.72-0.83). Similar AUC values were found if replacing DSHw with DVHw/DVHc/DSHc parameters. The impact of dose-volume/surface parameters remained when excluding patients with baseline IPSS ≥ 15 and in HYPO. IPSS ≥ 20 at the end of radiotherapy (n = 27/247) was mainly correlated to baseline IPSS and T stage. Conclusions Although the baseline IPSS was the main predictor, constraining v8.5w < 56 cc and v12.5w < 5 cc may significantly reduce acute GU toxicity.
AB - Background and purpose DUE01 is an observational study aimed at developing predictive models of genito-urinary toxicity of patients treated for prostate cancer with conventional (1.8-2 Gy/fr, CONV) or moderate hypo-fractionation (2.35-2.7 Gy/fr, HYPO). The current analysis focused on the relationship between bladder DVH/DSH and the risk of International Prostate Symptoms Score (IPSS) ≥ 15/20 at the end of radiotherapy. Materials and methods Planning and relevant clinical parameters were prospectively collected, including DVH/DSH, LQ-corrected (DVHc/DSHc) and weekly (DVHw/DSHw) histograms. Best parameters were selected by the differences between patients with/without IPSS ≥ 15/20 at the end of radiotherapy. Logistic uni- and backward multi-variable (MVA) analyses were performed. Results Data of 247 patients were available (CONV: 116, HYPO: 131). Absolute DVHw/DSHw and DVHc/DSHc predicted the risk of IPSS ≥ 15 at the end of radiotherapy (n = 77/247); an MVA model including baseline IPSS, anti-hypertensive, T stage, the absolute surface receiving ≥8.5 Gy/week and ≥12.5 Gy/week was developed (AUC = 0.78, 95% CI: 0.72-0.83). Similar AUC values were found if replacing DSHw with DVHw/DVHc/DSHc parameters. The impact of dose-volume/surface parameters remained when excluding patients with baseline IPSS ≥ 15 and in HYPO. IPSS ≥ 20 at the end of radiotherapy (n = 27/247) was mainly correlated to baseline IPSS and T stage. Conclusions Although the baseline IPSS was the main predictor, constraining v8.5w < 56 cc and v12.5w < 5 cc may significantly reduce acute GU toxicity.
KW - Dose-volume effects
KW - Prostate cancer
KW - Radiotherapy
KW - Urinary toxicity
UR - http://www.scopus.com/inward/record.url?scp=84902166089&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2014.02.006
DO - 10.1016/j.radonc.2014.02.006
M3 - Article
SN - 0167-8140
VL - 111
SP - 100
EP - 105
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -